By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Immunomedics, Inc. 

300 American Road

Morris Plains  New Jersey  07950-2450  U.S.A.
Phone: 201-605-8200 Fax: 973-605-8282


SEARCH JOBS


Industry
Biotechnology






Company News
Immunomedics, Inc. (IMMU) Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) In Patients With Metastatic Gastrointestinal Cancers 1/20/2015 7:12:48 AM
Immunomedics, Inc. (IMMU) Appoints Dr. Francois Wilhelm Chief Medical Officer 1/6/2015 7:32:08 AM
Immunomedics, Inc. (IMMU) Awarded Fast Track Designation By FDA For Sacituzumab Govitecan (IMMU-132) For Triple-Negative Breast Cancer Therapy 1/5/2015 7:07:39 AM
Immunomedics, Inc. (IMMU) Reports Preliminary Results From Pretargeted Imaging Study In Patients With Metastatic Breast Cancer 12/15/2014 7:32:09 AM
Immunomedics, Inc. (IMMU) Reports Expanded Phase 1/2 Trials Confirm Activity And Good Safety Profile Of Sacituzumab Govitecan (Immu-132) In Patients With Advanced Triple-Negative Breast Cancer 12/12/2014 7:39:35 AM
Immunomedics, Inc. (IMMU) To Present At 25th Annual Oppenheimer Healthcare Conference 12/5/2014 11:04:50 AM
Immunomedics, Inc. (IMMU) Announces Outcome Of 2014 Annual Meeting Of Stockholders 12/5/2014 9:51:43 AM
Immunomedics, Inc. (IMMU) Presents Clinical Data On Novel Antibody-Drug Conjugates For Solid Cancer Therapy 11/21/2014 11:51:27 AM
Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For Veltuzumab For The Treatment Of Pemphigus 11/21/2014 11:44:10 AM
Immunomedics, Inc. (IMMU) Presents Clinical Data On Novel Antibody-Drug Conjugates For Solid Cancer Therapy 11/20/2014 2:25:23 PM
12345678910...
//-->